Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity-Reference-Cited by-同舟云学术

Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity

Published:2018-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Li Zhihai,Song Shuo,He Maozhou,Wang Daning,Shi Jingjie,Liu Xinlin,Li Yunbing,Chi Xin,Wei Shuangping,Yang Yurou,Wang Zhiping,Li Jinjin,Qian Huilian,Yu Hai,Zheng Qingbing,Yan Xiaodong,Zhao Qinjian,Zhang Jun,Gu Ying,Li Shaowei^ORCID,Xia Ningshao^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07199-6.pdf

Reference68 articles.

1. World Health Organization. Pneumococcal vaccines WHO position paper--2012. Releve Epidemiol. Hebdomadaire 87, 129–144 (2012).

2. Schiller, J. T. & Muller, M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 16, e217–e225 (2015).

3. Kirchenbaum, G. A. & Ross, T. M. Eliciting broadly protective antibody responses against influenza. Curr. Opin. Immunol. 28, 71–76 (2014).

4. Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183–186 (2012).

5. Bommakanti, G. et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl Acad. Sci. USA 107, 13701–13706 (2010).

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59;Vaccine;2024-10

2. Risedronate-functionalized manganese-hydroxyapatite amorphous particles: A potent adjuvant for subunit vaccines and cancer immunotherapy;Journal of Controlled Release;2024-03

3. Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibody;Science Bulletin;2024-02

4. Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope;Scientific Reports;2023-10-05

5. Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions;Expert Review of Vaccines;2023-06-26